Compare Aon PLC (AON) vs AstraZeneca plc (AZN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aon PLC vs AstraZeneca plc — how do they compare? Aon PLC trades at $352.12 (market cap $75.61B), while AstraZeneca plc trades at $158.69 (market cap $248.14B). The key difference: AstraZeneca plc is far larger — about 3.3× Aon PLC's market cap, and AstraZeneca plc pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| AON | AZN | |
|---|---|---|
Market Cap | $75.61B | $248.14B |
Sector | Financials | Health |
52-Week High | $381.26 | $209.48 |
52-Week Low | $308.22 | $147.06 |
Enterprise Value | $90.22B | $275.41B |
Dividend Yield | 0.92% | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AON trades at $351.56, down 1.52% on the day, with a neutral technical signal and strong fundamentals including a 22.27% net income margin and consistent earnings beats. The stock shows robust profitability with ROE of 44.88% and revenue growth to $17.18B in 2025, though valuation multiples like a P/E of 19.65 and P/S of 4.37 reflect premium pricing. Recent news highlights institutional buying and Q2 2026 earnings beat, with organic revenue growth of 5% supporting positive sentiment.
Outlook remains favorable given earnings momentum and analyst consensus price target of $410, but risks include high valuation sensitivity and debt levels. The stock offers growth exposure with upside potential, balanced by execution risks in a competitive insurance brokerage sector.
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aon PLC
Aon is a leading global provider of insurance and reinsurance brokerage and human resource solutions. Its operations are tilted toward its brokerage operations. Headquartered in London, Aon has about 50,000 employees and operations in 120 countries around the world.
Read more on AON →About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →
